Researchers sought to determine whether the antisense oligonucleotide oblimersen can be added safely to conventional chemotherapy for older patients with AML.
At data cutoff, 562 of 626 patients enrolled in the study were eligible for primary endpoint assessment.
A single dose of cilta-cel yielded early, deep, and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma.
Researchers sought to identify patients with germline predisposition syndromes without syndromic features using an algorithmic approach compared with classic methods.
Researchers sought to determine whether GVHD prophylaxis with posttransplant cyclophosphamide following allo-HSCT would be associated with a higher risk of infection.
Researchers sought to determine whether FLAG-IDA with venetoclax would yield MRD-negative composite complete remission in patients with newly diagnosed AML.
Researchers sought to determine whether ixazomib and dexamethasone would be more effective vs physician’s choice of treatment in relapsed or refractory AL amyloidosis.
Researchers reviewed epitranscriptomics and the prospects of precision medicines that target AML-associated genes.
Researchers sought to determine whether acalabrutinib would be safe and effective in patients with treatment-naïve CLL who declined or were in ineligible for chemotherapy.
Results of a secondary analysis on oncology-patient communications regarding FS and PP concerns were presented at the 2021 ASCO Annual Meeting.
